Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959082 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma, sponsored by VSPharmTech Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06959082 is a Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma that is actively recruiting participants, run by VSPharmTech Co.. The registered enrollment target is 30 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06959082, a Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma, is actively recruiting participants, sponsored by VSPharmTech Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Radiation
- DRUG VS-101
Study Locations (3)
Connecticut
- Yale Cancer Center - New Haven
Kansas
- Cancer Center of Kansas - Wichita
New York
- NYU Langone Health - Manhattan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06959082
The ClinicalTrials.gov registry entry for NCT06959082 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VSPharmTech Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Cancer Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT06959082 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT06959082 about?
NCT06959082 is a clinical study titled "Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer". This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
What is the current status of trial NCT06959082?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-03. Estimated completion is 2027-06.
What conditions does trial NCT06959082 study?
This clinical trial studies the following conditions: Head and Neck Cancer Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06959082?
The interventions under investigation include: Cisplatin (DRUG), Radiation (RADIATION), VS-101 (DRUG).
Who is sponsoring clinical trial NCT06959082?
This trial is sponsored by VSPharmTech Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959082 being conducted?
This trial has 3 study locations across Connecticut, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.